The IL-23 inhibitor from AbbVie for patients 6 years of age and older with active psoriatic arthritis (PsA) or with moderate to severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy; and for adults with moderately to severely active Crohn's disease (CD) or with moderately to severely active ulcerative colitis (UC).1
FOR PATIENTS 6 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS (PsA)1
NOTHING IS EVERYTHING
Nothing less than the opportunity
to reach for their treatment goals.
For your patients,
that’s everything.
*"First-line" is defined as the first biologic prescription among patients who have not been prescribed biologics in the last 3 years.
†Source: IQVIA (NPA, NSP) and Symphony Health data through October 2025.
AFTER NSAIDs OR csDMARDs,
MAKE SKYRIZI YOUR FIRST CHOICE
FOR BIO-NAÏVE PATIENTS WITH PsA
Learn why rheumatologists may start with SKYRIZI
SUSTAINED
RELIEF IN JOINTS AND SKIN
IN ADULTS:
- ACR20 primary endpoint met at Week 241
- ACR20/50/70 and PASI 90 response rates at Week 24 and observed up to ~6 years3
SAFETY
AND TOLERABILITY
IN ADULTS:
- Up to ~6.5 years of PsA safety data and ~9 years in Ps4,‡
- Discontinuation rates evaluated at Week 24 and ~6.5 years in PsA5-7
- Safety profile of PsA at Week 24 was generally consistent with Ps at Week 161
SIMPLE
TO START
- Initially evaluate for TB, instruct patients to report signs and symptoms of infection, complete all age-appropriate vaccinations, and provide proper administration training1
- Quarterly dosing after 2 initiation doses at Weeks 0 and 41
‡Includes 6 PsA Phase 2-3 studies (including KEEPsAKE-1 and KEEPsAKE-2). Includes 23 Phase 1-4 studies in Ps encompassing 5 trials (including UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent), and 18 additional trials including LIMMitless.4
Skyrizi Complete
Skyrizi Complete provides you with a dedicated Field Reimbursement Manager and supports you throughout the prescription journey. Enroll your patient at the time of prescription by downloading the enrollment form to activate the 360 Access Support.
EXCEPTIONAL IMMUNOLOGY EXPERIENCE
IN RHEUMATOLOGY
*"First-line" is defined as the first biologic prescription among patients who have not been prescribed biologics in the last 3 years.
†Source: IQVIA (NPA, NSP) and Symphony Health data through October 2025.
IN GASTROENTEROLOGY
§Source: Symphony Health, an ICON plc Company, IDV®; Total Combined Prescription Count from July 2024 to September 2025.
IN DERMATOLOGY
Based on combined prescription data across Ps and PsA, excluding generics and OTC
||Source of data: Integrated Symphony Health as of 10/2025.
The term branded systemic is defined as systemic drugs that are sold by a specific name or trademark and protected by patent. OTC stands for over-the-counter medications.
SKYRIZI IS COVERED AS A
FIRST-LINE ADVANCED THERAPY¶
WITH NO REQUIREMENT OF A PRIOR BIOLOGIC, WITH
National Commercial and Medicare Part D Formulary coverage under the pharmacy benefit as of April 2026.11
¶First-line advanced therapies consist of PDE4is, TNFis, and other biologics.
#SKYRIZI is on a preferred tier or otherwise has preferred status on the plan's formulary.
**Coverage requirements and benefit designs vary by payer and may change over time.
Please consult with payers directly for the most current reimbursement policies.
WITH SKYRIZI COMPLETE, YOUR ELIGIBLE, COMMERCIALLY INSURED PATIENTS MAY PAY AS LITTLE AS $0 PER DOSE††
9 out
of 10
patients on SKYRIZI for PsA using the Complete copay program
PAID
$012‡‡
PER DOSE
††Eligibility: Eligibility restrictions and program limitations apply. Patient out-of-pocket expenses will vary depending on insurance coverage. For full Terms and Conditions, visit SKYRIZISavingsCard.com.
‡‡Based on commercial claims data from national data providers for filled SKYRIZI prescriptions for PsA for the period 5/2025-4/2026, inclusive of savings card redemptions. Among commercially insured PsA patients enrolled in Skyrizi Complete, 90% paid $0 out-of-pocket. Patients enrolled in maximizer programs are considered final out-of-pocket due to tertiary coverage, although claims data may reflect an out-of-pocket amount after copay support. Patient's actual out-of-pocket cost may vary depending on their insurance coverage and eligibility for support programs.